House dust mite-specific T-cell receptor (HDM-specific TCR)

T-cell receptors (TCRs) recognizing house dust mite (HDM)-derived peptides are specialized proteins on the surface of T lymphocytes that play a central role in the pathogenesis of allergic diseases [1.2.2, 1.4.2]. These receptors specifically bind to peptide fragments from major HDM allergens, such as Der p 1 and Der p 2, when they are presented by major histocompatibility complex (MHC) class II molecules on antigen-presenting cells [1.2.3, 1.5.3]. In sensitized individuals, this interaction typically activates a Th2-biased immune response, characterized by the secretion of pro-inflammatory cytokines like IL-4, IL-5, and IL-13, which drive IgE production and eosinophilic inflammation [1.2.3, 1.5.1]. Therapeutic interventions targeting these TCRs, most notably allergen-specific immunotherapy (AIT), aim to reprogram the immune system toward tolerance [1.1.4, 1.3.2]. This is achieved through the induction of regulatory T cells (Tregs) and a shift from Th2 to Th1 responses, effectively reducing clinical symptoms of allergic asthma and rhinitis upon subsequent allergen exposure [1.1.2, 1.3.2]. Modern approaches also explore peptide-based vaccines and TCR-specific modulators, such as TCR-V beta 3-CDR2 peptides, to precisely desensitize the immune system while minimizing the risk of systemic allergic reactions [1.2.1, 1.4.4]. By modulating the activity of these specific TCR clones, clinicians can achieve long-term disease modification in patients with allergic asthma and rhinitis [1.1.4, 1.5.1].

Other names

T-cell receptors recognizing house dust mite-derived peptidesMite-specific T-cell receptorDer p 1-specific T-cell receptorDer p 2-specific T-cell receptorHDM-reactive T-cell receptorHouse dust mite-specific TCR

Induction of immune tolerance through T-cell anergy, clonal deletion, or immune deviation from a Th2 to a Th1/Treg phenotype.